Compare WETH & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | HBIO |
|---|---|---|
| Founded | 1992 | 1901 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 24.9M |
| IPO Year | 2020 | 2000 |
| Metric | WETH | HBIO |
|---|---|---|
| Price | $1.36 | $6.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 126.6K | 26.1K |
| Earning Date | 04-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | $45,136,818.00 | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | $4.28 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.78 | $0.38 |
| 52 Week High | $3.68 | $7.50 |
| Indicator | WETH | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 53.07 |
| Support Level | $1.26 | $6.05 |
| Resistance Level | $1.46 | $7.00 |
| Average True Range (ATR) | 0.16 | 0.44 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 6.25 | 67.58 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.